

For Immediate Release
December 4, 2012

**SUNSHINE BIOPHARMA COMPLETES SIX IND-ENABLING STUDIES FOR ITS
ANTICANCER COMPOUND, Adva-27a**

Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed six IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate. Adva-27a is a small molecule that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR) in vitro. The six IND-Enabling studies completed include two physical characterizations, NMR and UV spectral analyses, and four biological activity assays comprised of Topoisomerase II inhibition studies with and without BSA, Tubulin assembly inhibition, and Cytotoxicity assays in MCF-7/MDR. These results and the results of other IND-Enabling studies currently in progress will form an integral part of an IND Application (Investigational New Drug Application) which the Company must file with the regulatory authorities in the US and Canada as part of the drug development and approval process.

"The results of these six IND-Enabling experiments confirm our previous observations that Adva-27a is an excellent anticancer drug candidate", said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "We are pressing ahead with our program", he added.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com